Drugmaker Novo Nordisk has revealed sales of its popular weight loss medicine doubled over the start of the year, driving higher earnings. The Danish company warned over supply constraints as it said it was seeing strong demand for its obesity treatments around the world. It reported net sales of 65.3 billion Danish krone (£7.5 billion) for the first quarter of 2023, nearly a quarter higher than the same period a year ago. Sales of obesity medicine Wegovy doubled to 9.4 billion Danish krone (£1.1 billion) from 4.6 billion Danish krone (£530 million) last year. Wegovy is an injection pen using the medicine semaglutide, and works by regulating people’s appetite and helping them feel fuller in between meals. It is a newly available treatment in the UK so is still monitored closely. Demand for Wegovy currently exceeds the supply, Novo Nordisk said, which led it to reduce the availability of lower-dose medicines in the US last year. It has started gradually increasing the supply this year and said it is investing in capacity to increase supply in the short term and in the future. Meanwhile, sales of alternative injection pen Ozempic soared by 43% to 27.8 billion Danish krone (£3.2 billion)...